Paul Schaper
Paul Schaper leads global policy efforts at Merck Sharp & Dohme on infectious diseases, including antibiotics/antifungals, HIV and hepatitis. Since 2013, he has served as the private sector representative on the board of the Global Fund for HIV, TB and Malaria. Schaper earned his B.A. and master’s degrees in public health policy and business administration from Emory University and another master’s degree in clinical psychology from Georgia State University.
Latest Articles
Opinion: How to generate increased investment to tackle antimicrobial resistance
over 8 years ago // Going for Goals
Increasing antimicrobial resistance is a continued threat to global health as well as economies. Merck Sharp & Dohme’s Paul Schaper believes increased investment is key, explaining the role both governments and the private sector need to play to ensure a healthy and prosperous future.